Abingworth’s Anthera Pharmaceuticals, Inc. ANTH Stock Holding History

Abingworth’s Portfolio ANTH Stock Details ANTH Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q1	–	Sell	-107,715	Closed	-$1.17M	–	19
2016 Q4	$1.17M	Buy	107,715 +43,710	+68%	+$757K	0.98%	13
2016 Q3	$1.53M	Buy	64,005 +9,256	+17%	+$233K	1.47%	15
2016 Q2	$1.35M	Hold	54,749	–	–	1.41%	17
2016 Q1	$1.58M	Hold	54,749	–	–	1.47%	14
2015 Q4	$2.03M	Hold	54,749	–	–	1.23%	15
2015 Q3	$2.67M	Hold	54,749	–	–	1.56%	11
2015 Q2	$3.77M	Hold	54,749	–	–	1.71%	11
2015 Q1	$1.96M	Hold	54,749	–	–	0.83%	13
2014 Q4	$679K	Hold	54,749	–	–	0.19%	15
2014 Q3	$832K	Hold	54,749	–	–	0.5%	12
2014 Q2	$1.49M	Hold	54,749	–	–	0.69%	11
2014 Q1	$1.47M	Hold	54,749	–	–	0.81%	12
2013 Q4	$1.34M	Hold	54,749	–	–	1.01%	9
2013 Q3	$1.76M	Hold	54,749	–	–	1%	8
2013 Q2	$1.73M	Buy	+54,749	New	+$2.04M	1.33%	8

Other funds holding ANTH

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Sabby Management Miami Beach, Florida $45.1M AUM 74.25% 1-Year Est. Return

RSCM

Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return

Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Abingworth's ANTH Position: Q1 2017 in Review

Abingworth sold out of Anthera Pharmaceuticals, Inc. (ANTH) in Q1 2017, closing a stake of 107,715 shares — an estimated $1.17M sold.

Abingworth first reported a position in ANTH in Q2 2013 and held it in 15 quarters. The position peaked at $3.77M in Q2 2015. 60 funds tracked by Wall St. Rank hold ANTH as of Q1 2017.

Abingworth reported no remaining Anthera Pharmaceuticals, Inc. position as of Q1 2017 after selling out during the quarter.
Abingworth sold 107,715 Anthera Pharmaceuticals, Inc. shares in Q1 2017, an estimated $1.17M.
Abingworth first reported a position in Anthera Pharmaceuticals, Inc. in Q2 2013 and held it in 15 quarters.
Abingworth's Anthera Pharmaceuticals, Inc. position peaked at $3.77M in Q2 2015.
60 funds tracked by Wall St. Rank held Anthera Pharmaceuticals, Inc. as of Q1 2017.

Based on Abingworth's 13F filing for Q1 2017, filed 15 May 2017.